147 related articles for article (PubMed ID: 26471877)
1. Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation validation.
Raj U; Kumar H; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2115-29. PubMed ID: 26471877
[TBL] [Abstract][Full Text] [Related]
2. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
3. An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures".
Gianti E; Zauhar RJ
J Comput Aided Mol Des; 2015 May; 29(5):451-70. PubMed ID: 25752764
[TBL] [Abstract][Full Text] [Related]
4. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
5. Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization.
Fahrenkamp D; Li J; Ernst S; Schmitz-Van de Leur H; Chatain N; Küster A; Koschmieder S; Lüscher B; Rossetti G; Müller-Newen G
Sci Rep; 2016 Oct; 6():35454. PubMed ID: 27752093
[TBL] [Abstract][Full Text] [Related]
6. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.
Smit LS; Meyer DJ; Billestrup N; Norstedt G; Schwartz J; Carter-Su C
Mol Endocrinol; 1996 May; 10(5):519-33. PubMed ID: 8732683
[TBL] [Abstract][Full Text] [Related]
7. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
Shao S; Yu R; Yu Y; Li Y
J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
[TBL] [Abstract][Full Text] [Related]
8. The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.
Gupta S; Yan H; Wong LH; Ralph S; Krolewski J; Schindler C
EMBO J; 1996 Mar; 15(5):1075-84. PubMed ID: 8605877
[TBL] [Abstract][Full Text] [Related]
9. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
[TBL] [Abstract][Full Text] [Related]
10. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3.
Wiederkehr-Adam M; Ernst P; Müller K; Bieck E; Gombert FO; Ottl J; Graff P; Grossmüller F; Heim MH
J Biol Chem; 2003 May; 278(18):16117-28. PubMed ID: 12591923
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.
Yesylevskyy SO; Ramseyer C; Pudlo M; Pallandre JR; Borg C
J Chem Inf Model; 2016 Aug; 56(8):1588-96. PubMed ID: 27479469
[TBL] [Abstract][Full Text] [Related]
12. Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain.
Delespine-Carmagnat M; Bouvier G; Bertoglio J
Eur J Immunol; 2000 Jan; 30(1):59-68. PubMed ID: 10602027
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
14. Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.
Szeląg M; Czerwoniec A; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2014 Oct; 740():417-20. PubMed ID: 25183399
[TBL] [Abstract][Full Text] [Related]
15. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
Fujitani Y; Hibi M; Fukada T; Takahashi-Tezuka M; Yoshida H; Yamaguchi T; Sugiyama K; Yamanaka Y; Nakajima K; Hirano T
Oncogene; 1997 Feb; 14(7):751-61. PubMed ID: 9047382
[TBL] [Abstract][Full Text] [Related]
16. An invertebrate signal transducer and activator of transcription 5 (STAT5) ortholog from the disk abalone, Haliotis discus discus: Genomic structure, early developmental expression, and immune responses to bacterial and viral stresses.
Bathige SD; Umasuthan N; Park HC; Lee J
Dev Comp Immunol; 2016 Mar; 56():46-56. PubMed ID: 26616564
[TBL] [Abstract][Full Text] [Related]
17. Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands.
John A; Vetrivel U; Subramanian K; Deepa PR
J Biomol Struct Dyn; 2017 May; 35(6):1350-1366. PubMed ID: 27145135
[TBL] [Abstract][Full Text] [Related]
18. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
19. High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains.
de Araujo ED; Manaswiyoungkul P; Israelian J; Park J; Yuen K; Farhangi S; Berger-Becvar A; Abu-Jazar L; Gunning PT
J Pharm Biomed Anal; 2017 Sep; 143():159-167. PubMed ID: 28600954
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
Zhang Y; Zhang TJ; Tu S; Zhang ZH; Meng FH
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
